We want to identify novel biomarkers of disease for diagnostic and monitoring purposes.
Whereas protein aggregation biomarkers are already available for clinical applications, we aim to extend this panel to biomarkers of cerebral vascular function and neuroinflammation. Together with genetic susceptibility and neuroimaging biomarkers, these will allow advanced phenotyping and will form the basis for personalized therapy. For this, we will continue our efforts to create unique patient cohorts and biobanks that are crucial to laboratory-supported phenotyping. Moreover, we will continue to embrace novel technologies (such as metabolomics, glycomics, big data analyses).